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Abstract
Background:  Carboxypeptidase 4 (CPA4)  is a zinc-dependent metallocarboxypeptidase on
chromosome 7q32 in a region linked to prostate cancer aggressiveness. CPA4 is involved in the
histone hyperacetylation pathway and may modulate the function of peptides that affect the growth
and regulation of prostate epithelial cells. We examined the association between genetic variation
in CPA4 and intermediate-to-high risk prostate cancer.
Methods: We studied 1012 men (506 cases and 506 controls) from Cleveland, Ohio. All cases had
Gleason ≥ 7, clinical stage ≥ T2c, or PSA ≥ 10 ng/mL at diagnosis. Six CPA4 single-nucleotide
polymorphisms were genotyped, and evaluated for their relation to prostate cancer. We also
evaluated whether CPA4 variants influence risk of disease among men diagnosed at an earlier age
(< 66 years).
Results: The nonsynonymous coding SNP (rs2171492, Cys303Gly) in CPA4 was associated with
an increased risk of aggressive prostate cancer among younger patients (< 66 years). Specifically,
men carrying the TT genotype had an approximately two-fold increased risk for being diagnosed
with intermediate-to-high risk disease (Odds Ratio = 1.83, p = 0.04). In the overall population (all
ages) none of the CPA4 SNPs demonstrated a statistically significant association with prostate
cancer.
Conclusion: Coding variation in CPA4 may confer increased risk of intermediate-to-high risk
prostate cancer among younger patients. Further work is needed to identify the functional aspects
of this variation and understand its biological effects on prostate cancer. Such work may translate
into more precise screening of higher risk individuals as well as guiding clinicians and patients
toward earlier and more definitive treatment modalities in patients genetically identified as higher
risk.
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Background
Prostate cancer is the most common malignancy among
men living in the United States. In 2008, an estimated
186,320 new cases of prostate cancer will be diagnosed,
and the disease is estimated to be responsible for 28,660
deaths.[1] Identifying which cases harbor potentially
aggressive disease versus those that will follow a more
indolent course is extremely important given the estab-
lished stage migration in prostate cancer as well as the
growing popularity of active surveillance and minimally
invasive therapies. Such knowledge would allow clini-
cians to more appropriately counsel patients and direct
more aggressive therapies to those most in need while
optimizing quality of life in those patients who are at
lower risk for disease aggressiveness.
Previous work has contributed greatly to our understand-
ing of disease aggressiveness and our ability to predict
clinical outcomes. [2-7] The most powerful predictor var-
iables have been a function of biochemical findings (PSA
level), low-magnification histologic architecture (Gleason
Grade), and physical exam findings (clinical T-stage). Pre-
dictive instruments (nomograms) have occasionally been
developed which include novel biochemical markers, but
these have generally offered only modest improvements
in predictive accuracies over previous nomograms and
have had limited generalizability.
The recent growth in our understanding of the human
genome.[8] provides an opportunity to further under-
stand the genetic basis of prostate cancer aggressiveness.
We previously undertook a genome-wide linkage study
and detected linkage between genetic markers on chromo-
some 7q32 and Gleason Grade (p = 0.0007).[9] This find-
ing suggests that the 7q32 region might harbor genes for
prostate cancer aggressiveness. Within this 7q32 region is
CPA4 (previously identified as CPA3), part of the carbox-
ypeptidase gene family and a strong candidate for the
putative prostate cancer aggressiveness gene.
Huang et al.[10] used mRNA differential display to iden-
tify genes induced by butyrate in androgen-independent
prostate cancer cells (PC-3). They found that during differ-
entiation and apoptosis CPA4 mRNA was highly up-regu-
lated. Meanwhile, they confirmed that CPA4 expression
was extremely low in normal prostate tissue by RT-PCR
analysis. They concluded that CPA4 appeared to be a
downstream gene in response to the hyperacetylating
activity of histones. Because of its structural homology to
other carboxypeptidases, CPA4 is thought to modulate
the function of peptide hormones that play an essential
role in the growth and/or differentiation of prostate epi-
thelial cells.[10] Natural substrates of carboxypeptidases
include kinins, enkephalin hexapeptides, anaphylatoxins,
and creatinine kinase.[11] CPA4 is imprinted preferen-
tially from the maternal allele, and is hypothesized to
impact prostate cancer aggressiveness.[12] While the spe-
cific ligand for CPA4 is yet to be discovered, there is a
known endogenous protein inhibitor, latexin.[13] In light
of this strong biological rationale, we present here the first
investigation of genetic variation in CPA4 and prostate
cancer aggressiveness.
Methods
The study was comprised of 1,012 men: 506 diagnosed
with intermediate-to-high risk prostate cancer (D'Amico
classification)[14] and 506 age-, ethnicity-, and hospital-
matched controls. All patients were recruited from the
major medical institutions of Cleveland, Ohio between
2001 and 2004. These cases are considered representative
of men diagnosed with intermediate-to-high risk prostate
cancer in the greater Cleveland region. Cases were defined
as newly diagnosed prostate cancer with histologically-
confirmed disease demonstrating any of the following:
Gleason score ≥ 7; clinical stage ≥ T2c; or PSA > 10 ng/ml
at diagnosis. Cases were promptly contacted following
diagnosis for inclusion in the study (median time from
diagnosis to recruitment was 4.7 months). The restriction
of cases to men with features of intermediate-risk and
high-risk disease was performed in effort to focus on the
most clinically relevant prostate cancers. To further focus
on such cancer, we also stratified our analyses by age of
onset (using 62 years as a cutpoint), and by whether the
cases had prostate cancer with Gleason ≤ 3+4 versus cases
with Gleason ≥ 4+3.
Controls were chosen among those who underwent
standard annual medical examinations at the collaborat-
ing institutions. Controls had no diagnosis of prostate or
any other non-skin cancers. All controls received a PSA
test and were referred for urologic consultation if their
PSA was ≥ 4 ng/mL. Controls were frequency matched to
cases by age (within 5 years), ethnicity, and medical insti-
tution. Institutional review board approval was obtained
from the participating institutions and all participants
gave informed consent. A more detailed description of
this study population has previously been reported.[15]
We used HapMap data http://www.hapmap.org/ and
HaploView to select haplotype tagging SNPs to evaluate
CPA4. We first selected single-nucleotide polymorphisms
across the CPA4 gene which had minor allele frequencies
(MAF) > 0.05. Seven SNPs in the Caucasian HapMap pop-
ulation (release #16) met this criterion. We eliminated
one synonymous SNP (rs2306848) from our analysis due
to difficulty in designing primers for the genotyping assay,
but replaced it with a highly correlated tag SNP rs1488009
tag SNP (r2 = 1). One of the SNPs included in our analysis
(rs2171492) is a nonsynonymous coding SNP
(Cys303Gly). Table 1 lists the six SNPs used for geneticBMC Cancer 2009, 9:69 http://www.biomedcentral.com/1471-2407/9/69
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analysis. The distribution of MAFs were relatively similar
among Caucasian and African American populations. The
correlation (D' and r2) between these SNPs are presented
[see Additional file 1]. Note that the second through sixth
SNPs cover a large haplotype block in European Ameri-
cans that spans much of CYPA4.
Genotyping was done by the 5' nuclease Taqman allelic
discrimination assay using the manufacturer's prede-
signed primer/probe sets, and assays were read on a 7900
HT Sequence Detection System (Applied Biosystems, Fos-
ter City, CA). All assays were performed by individuals
blinded to case-control status of the samples. The SNPs
were all in Hardy-Weinberg equilibrium among cases and
controls of each ethnic group (p > 0.05). For quality con-
trol, 2% replicate samples were included. The concord-
ance rate for replicate samples was 100%.
Odds ratios (ORs) and 95% confidence intervals (CIs)
were estimated by unconditional logistic regression to
examine the association between the CPA4 variants and
prostate cancer risk, adjusting for the matching factors.
Haplotype frequencies were estimated by the expectation-
maximization algorithm using the tagSNP software. Com-
mon haplotypes were defined as having a frequency ≥ 5%.
Haplotype dosage (i.e. an estimate of the number of cop-
ies of haplotype h) for each individual and each haplo-
type, h, was computed using that individual's genotype
data and haplotype frequency estimates obtained from
the E-M algorithm. All reported P-values are two-sided,
and all analyses were undertaken with SAS software (ver-
sion 9.1; SAS Institute, Inc, Cary, North Carolina).
Results
Baseline demographic characteristics for the 506 cases and
506 controls are presented in Table 2. The mean age was
65.7 years among cases and 65.5 years among controls.
82% of the study population was Caucasian and 18% was
African-American. A family history of prostate cancer
(defined as two or more 1st degree relatives or one 1st
degree relative and two or more 2nd degree relatives) was
more commonly reported among cases than controls (6%
vs. 1%, respectively). Eighty-four percent of cases had a
Gleason score of ≥ 7 and 36% had cT-stage ≥ T2. Two hun-
dred thirty-eight cases were diagnosed at age < 66 years; 40
(16.8%) of these patients were African-American.
Younger onset cases are of interest here, as these are more
likely to have a genetic basis to their disease.
Among younger men the rs2171492 nonsynonymous
coding SNP in CPA4 was associated with an increased risk
of intermediate-risk and high-risk prostate cancer (Table
3). When restricting our analyses to men either diagnosed
at age < 66 years (for cases) or enrolled into the study at
age < 66 (for controls) carrying the TT genotype for the
rs2171492 SNP versus the GG genotype gave a nearly two-
fold increased risk for aggressive disease (odds ratio =
1.83, 95% confidence interval 1.02–3.36, p = 0.04). This
association among younger men was strengthened when
further restricting our analyses to cases with the most
advanced disease (Gleason ≥ 4+3): men with the TT gen-
otype for the rs2171492 SNP versus the GG genotype gave
an odds ratio = 2.48 (95% confidence interval 1.14–5.40,
p = 0.02). When the analysis was applied the overall study
population (all ages), we did not observe any statistically
significant associations between CPA4 and prostate cancer
(Table 4).
To further investigate the association, we evaluated
whether haplotypes defined by the SNPs across CPA4
were associated with disease. Only one common haplo-
type with a 35.1% and 15.9% frequency among Cauca-
sian and African American men, respectively, contained
the rs2171492 T allele. Men carrying two copies of this
haplotype versus no copy was weakly associated with
intermediate-risk and high-risk prostate cancer among
men < 66 years of age (odds ratio = 1.82, 95% confidence
interval = 0.98–3.36, p = 0.06). This association was
slightly weaker than the result presented above for the
rs2171492 TT genotype alone, suggesting that this SNP
itself or another variant in linkage disequilibrium with the
SNP but not on the haplotype might explain the associa-
Table 1: Six CPA4 SNPs evaluated for association with aggressive prostate cancer
Minor Allele Frequency*
SNPs Position† Location Allele Change African Americans Caucasians
rs901799 129718638 5' C > A 0.13 0.15
rs3807344 129721455 intron A > G 0.17 0.11
rs1569132 129725280 intron A > G 0.39 0.43
rs1038628 129735249 intron G > T 0.20 0.40
rs2171492 129737976 exon§ A > G 0.35 0.36
rs1488009 129745334 intron G > T 0.23 0.38
*minor allele frequency among controls.
†SNP position based on dbSNP build 129.
§rs2171492 = Cys303GlyBMC Cancer 2009, 9:69 http://www.biomedcentral.com/1471-2407/9/69
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tion. Note also that restricting our analyses to Caucasians
did not materially change our results (not shown).
Discussion
This evaluation of genetic variants across CPA4 detected a
positive association between the nonsynonymous coding
SNP (Cys303Gly) rs2171492 and high risk prostate can-
cer among men with an earlier age of disease onset. More-
over, the SNP-level association was slightly stronger than
that observed for the common haplotype carrying this
SNP, suggesting that the SNP itself or another variant in
linkage disequilibrium with the SNP but not on the hap-
lotype may directly impact development of the more
aggressive forms prostate cancer. If this finding is repli-
cated by others, it would allow clinicians to focus treat-
ment efforts in these higher risk patients. The potential for
a direct relationship between a SNP and aggressive pros-
tate cancer provides impetus to evaluate the functionality
of this SNP.
CPA4 localizes to chromosome 7q32, a region that has
been previously identified as a candidate region for pros-
tate cancer aggressiveness.[9] CPA4 is upregulated by
sodium butyrate (a known histone deacetylase inhibitor,
HDACI) in treated cells from the androgen-independent
prostate cancer cell line PC-3.[10] HDACIs have been
studied extensively as potential chemotherapeutic and
chemopreventive agents for various cancers including
prostate cancer.[16,17] They have been shown to modify
the expression of different genes, inhibit the cell cycle, and
induce apoptosis in several cell lines.[18] Therefore, there
is a potential biological basis to suspect that the
rs2171492 SNP may alter the function of CPA4 with alter-
ations in cell cycle regulation and potential carcinogene-
sis.
In light of the heterogeneous nature of prostate can-
cer[18], it might be easiest to detect genetic risk factors for
this disease among earlier onset and more aggressive
cases. Furthermore, it is precisely in these younger and
more aggressive cases where early detection with defini-
tive therapeutic intervention stands to yield the greatest
impact on patients' lives. The identification of such
genetic risk factors may translate into more precise screen-
ing of higher risk individuals and guide clinicians and
Table 2: Characteristics of prostate cancer cases and controls included in association study
Cases (N = 506) Controls (N = 506)
Age (mean ± SD) 65.7 ± 8.2 65.6 ± 8.3
Ethnicity n (%)
African-American 89 (18) 89 (18)
Caucasian 417 (82) 417 (82)
Institution n (%)
Cleveland Clinic Foundation 407 (80) 407 (80)
University Hospitals, Cleveland 99 (20) 99 (20)
Family history of prostate cancer n (%)
Yes* 31 (6) 7 (1)
No 475 (94) 499 (99)
Tumor Stage† n (%)
T1 305 (60) NA
T2 145 (29) NA
T3 30 (6) NA
Gleason Score n (%)
53  ( 1 ) N A
6 79 (16) NA
7 314 (62) NA
8 67 (13) NA
93 9  ( 8 ) N A
10 4 (1) NA
PSA ng/ml (mean ± SD) 14.1 ± 27.4 1.7 ± 1.7
*1st degree relatives ≥ 2 or one 1st degree and 2nd degree relatives ≥ 2.
†Numbers do not add to 100% due to missing dataBMC Cancer 2009, 9:69 http://www.biomedcentral.com/1471-2407/9/69
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patients toward earlier and more definitive treatment
modalities in patients genetically identified as higher risk.
Conclusion
Our study suggests that the rs2171492 nonsynonymous
coding SNP in CPA4 confers an increased risk of high risk
prostate cancer among younger patients. Additional
research efforts are needed to confirm this finding, and if
confirmed identify the functional aspects of this variant
and understand their biological effects on prostate cancer.
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Table 3: Association between CPA4 variants and advanced prostate cancer, stratified by age at diagnosis (using 66 years as cutpoint)
Age < 66 years Age ≥ 66 years
SNP Genotype Cases Controls Odds Ratio
(95% CI)*
p-value Controls Cases Odds Ratio
(95% CI)*
p-value
rs901799 CC 178 (74.8) 173 (72.7) 1 199 (74.3) 185 (69.0) 1
CA 56 (23.5) 61
(25.6)
0.89 (0.59–1.36) 0.60 60
(22.4)
75 (28.0) 1.35 (0.91–2.00) 0.14
AA 4
(1.7)
4
(1.7)
0.98 (0.24–4.00) 0.98 9
(3.4)
8
(3.2)
0.96 (0.36–2.54) 0.93
rs3807344 AA 109 (45.8) 90
(37.8)
1 111 (41.4) 104 (38.8) 1
AG 98 (41.2) 120 (50.4) 0.67 (0.46–0.99) 0.05 124 (46.3) 123 (45.9) 1.06 (0.73–1.53) 0.76
GG 31 (13.0) 28
(11.8)
0.91 (0.51–1.64) 0.76 33
(12.3)
41 (15.3) 1.33 (0.78–2.26) 0.30
rs1569132 AA 85 (35.7) 82
(34.5)
18 3
(31.0)
87 (32.5) 1
AG 98 (41.2) 121 (50.8) 0.78 (0.52–1.17) 0.23 131 (48.9) 136 (50.8) 0.99 (0.67–1.46) 0.96
GG 55 (23.1) 35
(14.7)
1.51 (0.90–2.55) 0.12 54
(20.2)
45 (16.8) 0.80 (0.48–1.31) 0.37
rs1038628 GG 106 (44.5) 107 (45.0) 1 105 (39.2) 103 (38.4) 1
GT 91 (38.2) 102 (42.9) 0.91 (0.61–1.35) 0.62 119 (44.4) 129 (48.1) 1.11 (0.76–1.61) 0.60
TT 41 (17.2) 29
(12.2)
1.44 (0.82–2.53) 0.20 44
(16.4)
36 (13.4) 0.83 (0.49–1.41) 0.50
rs2171492 GG 107 (45.0) 108 (45.4) 1 104 (38.8) 109 (40.7) 1
GT 90 (37.8) 107 (45.0) 0.86 (0.58–1.27) 0.44 126 (47.0) 126 (47.0) 0.95 (0.66–1.38) 0.79
TT 41 (17.2) 23
(9.7)
1.83 (1.02–3.36) 0.04 38
(14.2)
33 (12.3) 0.83 (0.48–1.42) 0.49
rs1488009 AA 186 (78.2) 190 (79.8) 1 197 (73.5) 216 (80.6) 1
AG 49 (20.6) 46
(19.3)
1.09 (0.69–1.72) 0.71 68
(25.4)
44 (16.4) 0.58 (0.38–0.90) 0.01
GG 3
(1.3)
2
(0.8)
1.53 (0.25–9.31) 0.65 3
(1.1)
8
(3.0)
2.47 (0.64–9.46) 0.19
* From unconditional logistic regression model adjusted for age, ethnicity, and medical institution.BMC Cancer 2009, 9:69 http://www.biomedcentral.com/1471-2407/9/69
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